Study of Pre-clearance of Latent Tuberculosis Infection And BCG Revaccination
NCT ID: NCT01119521
Last Updated: 2017-01-09
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
82 participants
Study Classification
INTERVENTIONAL
Study Start Date
2010-10-31
Study Completion Date
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this research is to further study the tuberculosis (TB) vaccine, Bacillus Calmette Guérin (BCG). The goal of this study is to evaluate whether the BCG vaccine is more effective in preventing TB in adults if it is given after 6 months of treatment with a widely used anti-TB drug, isoniazid (INH). Participants will include 82 healthy, tuberculin skin test positive (TST+), HIV-uninfected, male and female volunteers, aged 18-40 years. The study will be conducted in Worcester, South Africa. Subjects will be assigned by chance to 1 of 2 possible treatment groups. Group 1 will receive 6 months of oral INH treatment followed by intradermal (administered into the skin) BCG revaccination and one year of follow-up. Group 2 will be observed for 7 months which will be followed by intradermal BCG revaccination and another 6 months of follow-up. Then 6 months of INH treatment will be given. Participants will be involved in study procedures for about to 22 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines
NCT05592223
Tuberculosis
COMPLETED
PHASE1
Immune Responses to Mycobacterium Tuberculosis (Mtb) in People With Latent Tuberculosis Infection With or Without Concomitant Helminth Infection
NCT02225158
Latent Tuberculosis Infection
TERMINATED
Tuberculosis Prevention for HIV Infected Adults
NCT00057122
HIV Infections
Tuberculosis
COMPLETED
PHASE3
First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b
NCT06050356
Healthy
RECRUITING
PHASE1
Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence
NCT03512249
Tuberculosis, Pulmonary
ACTIVE_NOT_RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is a phase I, single-center, open label, randomized controlled clinical trial assessing the effect of pre-clearance of latent Mycobacterium tuberculosis (MTB) by Isoniazid, isonicotinic acid hydrazine (INH) treatment before Bacillus Calmette-Guérin (BCG) revaccination versus BCG revaccination alone on mycobacterial-specific immune responses in tuberculin skin test (TST) positive adults. Subjects initially assigned to observation prior to BCG revaccination will receive INH treatment of latent tuberculosis infection (LTBI) beginning six months after revaccination. Volunteers will include 82 healthy, TST positive human immunodeficiency virus (HIV)-uninfected, male and female persons aged 18-40 years. The primary objectives of the study are to: determine the effect of INH preclearance on the kinetics and characteristics of the specific immune response following BCG revaccination in adults with latent MTB infection (TST positive); and determine the safety and reactogenicity of BCG revaccination in TST positive adults. The secondary objectives of the study are to: determine the effect of INH preclearance and BCG revaccination on MTB-specific Th1 effector and central memory cell function; determine the effect of INH preclearance and BCG revaccination on MTB-specific Treg cell function; and determine the effect of INH preclearance and BCG revaccination on innate immune responses as measured by T cell mediated inhibition of intracellular mycobacterial growth and inflammatory cytokine production. All subjects are expected to be enrolled over 12 months. The duration of screening, enrollment, and follow-up for subjects is up to 22 months. Subjects will be randomly assigned to receive either: 6 months of INH treatment for LTBI (completed within no more than 7 months) followed by intradermal BCG revaccination or 7 months of observation (run in period) followed by intradermal BCG revaccination followed after 6 months of observation by 6 months of INH treatment for LTBI. Both groups will receive their BCG vaccinations during the same time period. Volunteers will be evaluated at 7 and 14 days and 1, 3, 6 and/or 12 months after BCG revaccination and each month of INH therapy and the end of study for safety, reactogenicity and immunogenicity. Blood for immunologic studies will be drawn at study enrollment for subjects, just prior to BCG revaccination, and 1, 2 weeks and 1, 3 and either 6 or 12 months (depending on which study arm) after BCG vaccination, and months 1, 3, 6 of INH therapy and the end of study for measurement of MTB specific T cell responses. Both treatment arms will be followed for safety and immunogenicity endpoints for 12 months after BCG revaccination. Immunologic outcomes have been chosen with the goal of measuring the characteristics and kinetics of human immune responses following BCG vaccination to support the ultimate aim of developing methods to determine the biological relevance of immune responses induced by BCG revaccination and their relevance to protection from tuberculosis (TB). Overall, this study may provide key information on the characteristics and kinetics of immune responses following BCG revaccination in adults and whether these are affected by preclearance with INH treatment of LTBI.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Tuberculosis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A: INH; BCG
6 months of Isoniazid (INH) treatment for latent tuberculosis infection (LTBI) (completed within no more than 7 months) followed by intradermal Bacillus Calmette-Guérin (BCG) revaccination.
Group Type
EXPERIMENTAL
BCG strain Danish
Intervention Type
BIOLOGICAL
Intradermal Bacillus Calmette-Guerin (BCG) live-attenuated vaccine prepared using the Danish 1331 BCG substrain; adult dose contains 2 to 8 x 10\^5 colony forming units (CFU) BCG.
Isoniazid
Intervention Type
DRUG
United States Pharmacopeia 100 mg or 300 mg oral tablets \[5 mg/kilogram/day (rounded up to nearest 100 mg; maximum dose 300 mg/day)\].
Group B: observation; BCG; observation; INH
7 months of observation (run in period) followed by intradermal Bacillus Calmette-Guérin (BCG) revaccination followed after 6 months of observation by 6 months of Isoniazid (INH) treatment for latent tuberculosis infection (LTBI).
Group Type
EXPERIMENTAL
BCG strain Danish
Intervention Type
BIOLOGICAL
Intradermal Bacillus Calmette-Guerin (BCG) live-attenuated vaccine prepared using the Danish 1331 BCG substrain; adult dose contains 2 to 8 x 10\^5 colony forming units (CFU) BCG.
Isoniazid
Intervention Type
DRUG
United States Pharmacopeia 100 mg or 300 mg oral tablets \[5 mg/kilogram/day (rounded up to nearest 100 mg; maximum dose 300 mg/day)\].
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BCG strain Danish
Intradermal Bacillus Calmette-Guerin (BCG) live-attenuated vaccine prepared using the Danish 1331 BCG substrain; adult dose contains 2 to 8 x 10\^5 colony forming units (CFU) BCG.
Intervention Type
BIOLOGICAL
Isoniazid
United States Pharmacopeia 100 mg or 300 mg oral tablets \[5 mg/kilogram/day (rounded up to nearest 100 mg; maximum dose 300 mg/day)\].
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Males and non-pregnant, non-lactating females aged 18 to 40 years, inclusive.
2. Be available for study follow-up.
3. Be in good general health as judged by a physician on the basis of reported medical history and physical examination including blood pressure (BP) and respiratory evaluation.
4. Have a visible Bacillus Calmette-Guérin (BCG) scar. Subjects with medical documentation of BCG vaccination after 2 years of age will be excluded.
5. Have a positive (greater than or equal to 15 mm induration at 48 to 72 hours after placement) tuberculin skin test \[TST; Mantoux method using 2 tuberculin units (TU) Purified Protein Derivative (PPD) RT-23\].
6. Weigh at least 45 kg.
7. Negative human immunodeficiency virus (HIV) approved test.
8. Demonstrate adequate understanding of the study and its requirements for participation, as demonstrated by discussions with study staff, and be able to provide written informed consent to participate in the study.
9. Females must not be pregnant, as determined by negative pregnancy test at screening, have a negative urine pregnancy test on the day of BCG revaccination, and must be non-lactating. For women of child bearing potential, use an effective contraception (licensed hormonal treatment, monogamous relationship with vasectomized partner, surgical sterilization) for 30 days prior to immunization and for the 2-year period of study follow-up.
10. Serum aspartate aminotransferase (AST) or alanine transaminase (ALT) \< 1.1 x upper limit of normal (ULN) and serum total bilirubin \< 1.1 x ULN.
11. Serum creatinine \< 1.5 mg/dL; urinalysis dipstick negative for glucose and 1 plus protein.
12. Total white blood cell (WBC) count \> 3.5 x 10\^3/mm\^3 and \< 10.8 x 10\^3/mm\^3.
13. Hemoglobin \> 12 gm/dL (female) and \> 13.5 gm/dL (male).
14. Have negative serologic tests for hepatitis B surface antigen and hepatitis C antibody.
2. Be available for study follow-up.
3. Be in good general health as judged by a physician on the basis of reported medical history and physical examination including blood pressure (BP) and respiratory evaluation.
4. Have a visible Bacillus Calmette-Guérin (BCG) scar. Subjects with medical documentation of BCG vaccination after 2 years of age will be excluded.
5. Have a positive (greater than or equal to 15 mm induration at 48 to 72 hours after placement) tuberculin skin test \[TST; Mantoux method using 2 tuberculin units (TU) Purified Protein Derivative (PPD) RT-23\].
6. Weigh at least 45 kg.
7. Negative human immunodeficiency virus (HIV) approved test.
8. Demonstrate adequate understanding of the study and its requirements for participation, as demonstrated by discussions with study staff, and be able to provide written informed consent to participate in the study.
9. Females must not be pregnant, as determined by negative pregnancy test at screening, have a negative urine pregnancy test on the day of BCG revaccination, and must be non-lactating. For women of child bearing potential, use an effective contraception (licensed hormonal treatment, monogamous relationship with vasectomized partner, surgical sterilization) for 30 days prior to immunization and for the 2-year period of study follow-up.
10. Serum aspartate aminotransferase (AST) or alanine transaminase (ALT) \< 1.1 x upper limit of normal (ULN) and serum total bilirubin \< 1.1 x ULN.
11. Serum creatinine \< 1.5 mg/dL; urinalysis dipstick negative for glucose and 1 plus protein.
12. Total white blood cell (WBC) count \> 3.5 x 10\^3/mm\^3 and \< 10.8 x 10\^3/mm\^3.
13. Hemoglobin \> 12 gm/dL (female) and \> 13.5 gm/dL (male).
14. Have negative serologic tests for hepatitis B surface antigen and hepatitis C antibody.
Exclusion Criteria
1. Known hypersensitivity to Isoniazid (INH) or to any component of Bacillus Calmette-Guérin (BCG) vaccine.
2. Exposure to a case of Tuberculosis (TB) with known INH resistance.
3. Current smear or culture-confirmed or clinically diagnosed active TB
4. Suspected active TB (recurrent fever, fatigue, night sweats, weight loss, oral ulcers, diarrhea, nausea or vomiting, bleeding) or patients who are receiving anti-tuberculosis drugs.
5. Prior TB treatment, prior treatment for latent tuberculosis infection (LTBI), a self-reported history or vaccination card or medical record documenting receipt of BCG vaccination after 2 years of age.
6. Pregnant or nursing females.
7. Chronic immunosuppressive disorder or a condition requiring chronic immunosuppressive treatment such as rheumatoid arthritis or severe asthma requiring chronic corticosteroid therapy. For corticosteroids, this will mean prednisone, or equivalent, 0.5 mg/kg/day or daily use of inhaled corticosteroids. Topical steroids are allowed.
8. Active dermatitis such as atopic dermatitis.
9. Persons with any history of scarring badly or keloid formation based on physical examination.
10. Receipt of blood products or immunoglobulin within six months of BCG revaccination.
11. History of chronic illness requiring close physician follow up, including known chronic liver disease or cirrhosis, or any medical, psychiatric, occupational, or substance abuse problems that make it unlikely the volunteer will comply with the protocol as determined by the local investigator.
12. History of acute or chronic medical conditions including, but not limited to diabetes mellitus, chronic renal failure/dialysis, silicosis, gastrectomy, jejunoileal bypass, solid organ transplantation such as renal or cardiac transplants, carcinoma of the head and neck, and disorders of the liver, kidney, lung, heart, or nervous system, or other metabolic or autoimmune/inflammatory conditions.
13. Have any systemic symptoms including fever, myalgia, fatigue, chills, night sweats, weight loss, nausea, vomiting or bleeding, diarrhea, abdominal pain, rhinorrhea, cough, wheezing, or shortness of breath within 72 hours before vaccination or signs of mucosal ulceration, lymphadenitis, gastrointestinal, or pulmonary disease by physical examination on day of vaccination. Subjects with minor self-limited illnesses such as common colds or gastroenteritis may return for re-evaluation after 3 days if their symptoms have abated for vaccination.
14. Have lymphadenopathy, hepatosplenomegaly, or other abnormalities on physical examination.
15. Have close contacts, with confirmed or suspected, human immunodeficiency virus (HIV) infection or other immunodeficiency state (including diabetes mellitus, chronic dermatitis/severe eczema, chronic renal failure, hematologic malignancy), or on chronic immunosuppressive therapy. A close contact is defined as a person who lives in the same home as the subject.
16. Live in a household where any household member has been diagnosed or treated for active TB during the previous 2 years.
17. Have received or currently be receiving chronic (more than 14 days) immunosuppressive therapy within 6 months prior to screening. This includes chronic treatment with oral prednisone 0.5 mg/kg/day (or equivalent). Inhaled and topical steroids are allowed.
18. Persons with chronic heavy ethanol intake or injection drug use. Chronic heavy ethanol intake is defined as an average continuous daily intake of more than 2 drinks, or a pattern of ethanol use, which, in the opinion of the investigator would prejudice his or her participation in the trial. Injection drug use will be defined as any non-medical injection drug use during the previous 2 years.
19. Participated in another research study that includes receiving an experimental drug within 30 days prior to study entry.
20. Receipt of live attenuated vaccines within 60 days of study entry. Note: Medically indicated inactivated vaccines are not exclusionary, but should be given at least 2 weeks away from BCG revaccination, or any immunologic sampling time point post BCG revaccination.
21. Have a history of the use of a systemic antibiotic within the 14 days prior to revaccination or planned use of a systemic antibiotic in the 3 months after revaccination.
2. Exposure to a case of Tuberculosis (TB) with known INH resistance.
3. Current smear or culture-confirmed or clinically diagnosed active TB
4. Suspected active TB (recurrent fever, fatigue, night sweats, weight loss, oral ulcers, diarrhea, nausea or vomiting, bleeding) or patients who are receiving anti-tuberculosis drugs.
5. Prior TB treatment, prior treatment for latent tuberculosis infection (LTBI), a self-reported history or vaccination card or medical record documenting receipt of BCG vaccination after 2 years of age.
6. Pregnant or nursing females.
7. Chronic immunosuppressive disorder or a condition requiring chronic immunosuppressive treatment such as rheumatoid arthritis or severe asthma requiring chronic corticosteroid therapy. For corticosteroids, this will mean prednisone, or equivalent, 0.5 mg/kg/day or daily use of inhaled corticosteroids. Topical steroids are allowed.
8. Active dermatitis such as atopic dermatitis.
9. Persons with any history of scarring badly or keloid formation based on physical examination.
10. Receipt of blood products or immunoglobulin within six months of BCG revaccination.
11. History of chronic illness requiring close physician follow up, including known chronic liver disease or cirrhosis, or any medical, psychiatric, occupational, or substance abuse problems that make it unlikely the volunteer will comply with the protocol as determined by the local investigator.
12. History of acute or chronic medical conditions including, but not limited to diabetes mellitus, chronic renal failure/dialysis, silicosis, gastrectomy, jejunoileal bypass, solid organ transplantation such as renal or cardiac transplants, carcinoma of the head and neck, and disorders of the liver, kidney, lung, heart, or nervous system, or other metabolic or autoimmune/inflammatory conditions.
13. Have any systemic symptoms including fever, myalgia, fatigue, chills, night sweats, weight loss, nausea, vomiting or bleeding, diarrhea, abdominal pain, rhinorrhea, cough, wheezing, or shortness of breath within 72 hours before vaccination or signs of mucosal ulceration, lymphadenitis, gastrointestinal, or pulmonary disease by physical examination on day of vaccination. Subjects with minor self-limited illnesses such as common colds or gastroenteritis may return for re-evaluation after 3 days if their symptoms have abated for vaccination.
14. Have lymphadenopathy, hepatosplenomegaly, or other abnormalities on physical examination.
15. Have close contacts, with confirmed or suspected, human immunodeficiency virus (HIV) infection or other immunodeficiency state (including diabetes mellitus, chronic dermatitis/severe eczema, chronic renal failure, hematologic malignancy), or on chronic immunosuppressive therapy. A close contact is defined as a person who lives in the same home as the subject.
16. Live in a household where any household member has been diagnosed or treated for active TB during the previous 2 years.
17. Have received or currently be receiving chronic (more than 14 days) immunosuppressive therapy within 6 months prior to screening. This includes chronic treatment with oral prednisone 0.5 mg/kg/day (or equivalent). Inhaled and topical steroids are allowed.
18. Persons with chronic heavy ethanol intake or injection drug use. Chronic heavy ethanol intake is defined as an average continuous daily intake of more than 2 drinks, or a pattern of ethanol use, which, in the opinion of the investigator would prejudice his or her participation in the trial. Injection drug use will be defined as any non-medical injection drug use during the previous 2 years.
19. Participated in another research study that includes receiving an experimental drug within 30 days prior to study entry.
20. Receipt of live attenuated vaccines within 60 days of study entry. Note: Medically indicated inactivated vaccines are not exclusionary, but should be given at least 2 weeks away from BCG revaccination, or any immunologic sampling time point post BCG revaccination.
21. Have a history of the use of a systemic antibiotic within the 14 days prior to revaccination or planned use of a systemic antibiotic in the 3 months after revaccination.
Minimum Eligible Age
18 Years
Maximum Eligible Age
40 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Cape Town - Institute of Infectious Disease and Molecular Medicine
Cape Town, Western Cape, South Africa
Site Status
Countries
Review the countries where the study has at least one active or historical site.
South Africa
References
Explore related publications, articles, or registry entries linked to this study.
Suliman S, Geldenhuys H, Johnson JL, Hughes JE, Smit E, Murphy M, Toefy A, Lerumo L, Hopley C, Pienaar B, Chheng P, Nemes E, Hoft DF, Hanekom WA, Boom WH, Hatherill M, Scriba TJ. Bacillus Calmette-Guerin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses. J Immunol. 2016 Aug 15;197(4):1100-1110. doi: 10.4049/jimmunol.1501996. Epub 2016 Jul 13.
Reference Type
RESULT
Johnson JL, Geldenhuys H, Thiel BA, Toefy A, Suliman S, Pienaar B, Chheng P, Scriba T, Boom WH, Hanekom W, Hatherill M. Effect of isoniazid therapy for latent TB infection on QuantiFERON-TB gold in-tube responses in adults with positive tuberculin skin test results in a high TB incidence area: a controlled study. Chest. 2014 Mar 1;145(3):612-7. doi: 10.1378/chest.13-1232.
Reference Type
RESULT
Hatherill M, Geldenhuys H, Pienaar B, Suliman S, Chheng P, Debanne SM, Hoft DF, Boom WH, Hanekom WA, Johnson JL. Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults. Vaccine. 2014 Jun 30;32(31):3982-8. doi: 10.1016/j.vaccine.2014.04.084. Epub 2014 May 9.
Reference Type
RESULT
Suliman S, Murphy M, Musvosvi M, Gela A, Meermeier EW, Geldenhuys H, Hopley C, Toefy A, Bilek N, Veldsman A, Hanekom WA, Johnson JL, Boom WH, Obermoser G, Huang H, Hatherill M, Lewinsohn DM, Nemes E, Scriba TJ. MR1-Independent Activation of Human Mucosal-Associated Invariant T Cells by Mycobacteria. J Immunol. 2019 Dec 1;203(11):2917-2927. doi: 10.4049/jimmunol.1900674. Epub 2019 Oct 14.
Reference Type
DERIVED
Scriba TJ, Penn-Nicholson A, Shankar S, Hraha T, Thompson EG, Sterling D, Nemes E, Darboe F, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Johnson JL, Boom WH, Hatherill M, Valvo J, De Groote MA, Ochsner UA, Aderem A, Hanekom WA, Zak DE; other members of the ACS cohort study team. Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease. PLoS Pathog. 2017 Nov 16;13(11):e1006687. doi: 10.1371/journal.ppat.1006687. eCollection 2017 Nov.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
07-0083
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Treatment of Latent Tuberculosis Infection With Isoniazid
NCT00293228
COMPLETED
PHASE4
A Phase II Study of H56:IC31 in Healthy Adolescents
NCT03265977
WITHDRAWN
PHASE2
Training Protocol on the Natural History of Tuberculosis
NCT01212003
RECRUITING
Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation
NCT02231229
COMPLETED
PHASE4
A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)
NCT05284812
SUSPENDED
PHASE2
Expression of Tuberculosis in the Lung
NCT00201253
COMPLETED
Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients
NCT04538911
ACTIVE_NOT_RECRUITING
PHASE1
A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis(TB) Subunit Vaccine
NCT01003093
COMPLETED
PHASE1
A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers
NCT00929396
COMPLETED
PHASE1
Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease
NCT01424501
TERMINATED
PHASE2
Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients
NCT00265226
COMPLETED
PHASE3
Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers
NCT05537038
COMPLETED
PHASE1
Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana
NCT00164281
COMPLETED
PHASE4
Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung
NCT05027958
COMPLETED
EARLY_PHASE1
TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB
NCT03251196
UNKNOWN
Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention
NCT05413551
COMPLETED
PHASE1
The Correlate of Risk Targeted Intervention Study
NCT02735590
UNKNOWN
PHASE2/PHASE3
Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
NCT00023452
COMPLETED
PHASE3
Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.
NCT00341328
COMPLETED
PHASE3
A Trial of Isoniazid for the Reversion of Interferon Gamma ELISPOT in Tuberculosis (TB) Case Contacts
NCT00130325
COMPLETED
NA
Immune Response to Mycobacterium Tuberculosis Infection
NCT00257907
COMPLETED
A Safety and Immunogenicity Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)
NCT01049282
COMPLETED
PHASE1
Relevance of Isoniazid Dosage in Adults Treated for Tuberculosis
NCT06054334
UNKNOWN
High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis
NCT00513396
COMPLETED
PHASE2/PHASE3
A Trial of the C-Tb Skin Test, When Given Intradermally to Healthy Volunteers Previously Vaccinated With BCG
NCT01242475
COMPLETED
PHASE2